A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes

Overview

Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology are delighted to announce the return of e-SPACE Heart Failure to be held 20-21 October 2023.

Last year’s event brought together over 60 leading experts from around the world and a live global audience of thousands. Click here to watch e-SPACE Heart Failure 2022 on-demand.

e-SPACE Heart Failure 2023 will continue to deliver best-in-class free-to-access virtual education and will both optimise geographical reach whilst delivering both global and regional insight. A thoughtfully curated programme will support the exploration of how leading experts are implementing the new heart failure guidelines into clinical practice, as well as aiding the discovery of the latest information on patient profiling in heart failure for tailoring medical therapy.

Following on from the huge success of last year, this event will once again bring together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.

Underpinned by this combined expertise in educational content and delivery, and led by an international faculty of global standing, e-SPACE Heart Failure 2023 promises to be the widest reaching and most engaging to date.

The e-SPACE HF 2023 conference has been accredited by EBAC® for a maximum of 10 CE credits.

Programme

(Please note this programme is subject to change)

Change your timezone preference

Day 1

9:00 AM - 10:00 AM (BST)
Plenary Session
Part 1: Session 1 - Recent guideline updates in HF

Chairs – Ahmed Bennis and Frieder Braunschweig

  • ESC Guidelines update – Marco Metra
  • New consensus on HF management of Australian clinicians – Alicia Chan
  • Acute heart failure and valvular heart disease: a scientific statement of the Heart Failure Association – Ovidiu Chioncel
  • Patient phenotyping in HFpEF – Stefan Anker


10:10 AM - 10:50 AM (BST)
Scientific Session - Meet the Experts
Iron Deficiency & IV Iron – The 2023 ESC HF Guidelines and Recent Trial Results: Interpretation & Implementation

  • Welcome and introduction - Patricia Campbell 
  • Review of ESC 2023 guideline update on IV iron - Paul Kalra  
  • Heart-FID and 2023 meta-analysis - Robert John Mentz  
  • Panel discussion 


Supported by an unrestricted educational grant from Pharmacosmos


11:00 AM - 12:00 PM (BST)
Plenary Session
Part 1: Session 2 - GDMT in the clinical setting

Chairs – Michael Böhm and Frieder Braunschweig

  • Foundational therapies in HFrEF – John McMurray
  • Individualising GDMT implementation – Gianluigi Savarese
  • Learnings from STRONG HF – Marianna Adamo


12:10 PM - 1:00 PM (BST)
Special Live Interactive Session
Management of ATTR-CM

  • Welcome and introduction - Brett Sperry 
  • Understanding ATTR amyloidosis and its burden - Arnt Kristen 
  • Diagnosis state of the art approaches - Fabian Knebel 
  • Management of ATTR-CM: the present and future - Ahmad Masri 
  • Panel discussion 


1:10 PM - 1:50 PM (BST)
Meet the Expert
Best practices in the management of patients with cardiac amyloidosis

  • Welcome and introduction - Peter Van De Meer 
  • Early identification / diagnosis in practice - Daniela Tomasoni 
  • Management of ATTR-CM: best practices - Marianna Fontana 
  • Panel discussion 


Supported by an unrestricted educational grant from AstraZeneca


2:00 PM - 3:00 PM (BST)
Plenary Session
Part 2: Session 3 - SGLT2i in clinical practice

Chairs – Stefan Anker and Clara Ines Saldarriaga

  • SGLT2 inhibition in 2023: what’s exciting? – Milton Packer
  • Early initiation to achieve rapid clinical benefits – Shelley Zieroth
  • What about HF with improved ejection fraction? – Muthiah Vaduganathan
  • Sotaglifozin: what’s new? – Deepak Bhatt


3:10 PM - 3:50 PM (BST)
Meet the Expert
Management of patients with HFpEF: What did we learn from our HFrEF patients

  • Welcome and introduction - Giuseppe Rosano
  • Barriers for implementation - Clara Ines Saldarriaga 
  • Learnings from HFrEF for HFpEF - Gianluigi Savarese 
  • Panel discussion 


Supported by an unrestricted educational grant from AstraZeneca


4:00 PM - 5:00 PM (BST)
Plenary Session
Part 2: Session 4 - Obesity and weight management in HF

Chairs – Mikhail Kosiborod and Stefan Anker

  • Obesity and heart failure: epidemiology and mechanisms – Massimo Piepoli
  • Weight gain / weight loss in HF – Giulia Ferrannini
  • The obesity paradox – Wolfram Doehner
  • Overview of current therapeutic agents – Mark Petrie


5:10 PM - 6:00 PM (BST)
Special Live Interactive Session
Best practices for hyperkalemia management across the cardiorenal spectrum

  • Welcome and introduction - Giuseppe Rosano 
  • The international Delphi consensus on hyperkalemia - Gianluigi Savarese 
  • Practical tools for Raasi optimisation - Ileana Piña 
  • Panel discussion 


7:00 PM - 8:00 PM (BST)
Plenary Session
Part 3: Session 5 - Worsening and acute heart failure

Chairs – Gerasimos Filippatos and Ileana Pina

  • HFA clinical statement on worsening HF – Marianna Adamo
  • SGLT2s in patients hospitalised for acute HF – Piotr Ponikowski
  • Vericiguat: the 5th pillar? – Javed Butler
  • Omecamtiv Mecarbil: what’s next? – John Teerlink


9:00 PM - 10:00 PM (BST)
Scientific Session - Meet the Experts
Iron Deficiency & IV Iron – The 2023 ESC HF Guidelines and Recent Trial Results: Interpretation & Implementation

  • Welcome and introduction - Patricia Campbell 
  • Review of ESC 2023 guideline update on IV iron - Paul Kalra  
  • Heart-FID and 2023 meta-analysis - Robert John Mentz  
  • Panel discussion 


Supported by an unrestricted educational grant from Pharmacosmos



Day 2

8:20 AM - 8:50 AM (BST)
Meet the Expert
Iron deficiency and heart failure – what we have learnt so far?

  • Welcome and introduction - Ovidiu Chioncel 
  • Clinical impact and treatment of iron deficiency in heart failure - Piotr Ponikowski
  • Management of iron deficiency in heart failure - guidelines and practical considerations - Andrew Sindone 
  • Panel discussion 


Supported by an unrestricted educational grant from CSL Vifor


9:00 AM - 10:00 AM (BST)
Plenary Session
Part 4: Session 6 - Iron deficiency: the totality of evidence

Chairs – Piotr Ponikowski and Yuhui Zhang

  • Iron deficiency and cardiovascular processes: what have we learnt so far? – Ewa Jankowska
  • Latest data on ferric derisomaltose – John Cleland
  • IV iron in HF: insights from recent meta analysis – Piotr Ponikowski
  • What about dose? – Stephan von Haehling


10:10 AM - 10:50 AM (BST)
Meet the Expert
Practical approaches in the management of hyperkalemia

  • Welcome and introduction: hyperkalemia in the setting of HF - Shelley Zieroth 
  • Practical approaches to hyperkalemia management: the example of the Princess of Wales Hospital - Aaron Wong 
  • Panel discussion 


Supported by an unrestricted educational grant from AstraZeneca


11:00 AM - 12:00 PM (BST)
Plenary Session
Part 4: Session 7 - Managing comorbidities in HF

Chairs – Harriette van Spall and Brenda Moura

  • New MRAs for the management of patients with T2D and CKD – Gerasimos Filippatos
  • Focus on hypertension – Michael Böhm
  • Managing hyperkalemia – Joao Ferreira


2:00 PM - 3:00 PM (BST)
Plenary Session
Part 5: Session 8 - Devices in HF: time to reassess their place?

Chairs – Javed Butler and Giuseppe Rosano

  • Neuromodulation therapy for HFrEF – Javier de Juan Bagudá
  • CCM: benefits of early implementation – Marat Fudim
  • Interatrial shunts – William Abraham


3:10 PM - 3:50 PM (BST)
Meet the Expert
What happens if you fix FMR , but ignore the root cause of heart failure?

  • Welcome and introduction: Stefan Anker 
  • The EMPOWER Trial: providing the clarity needed in the TMVr space: Javed Butler 
  • Carillon: a simple, low risk intervention with dual benefits: Klaus Witte 
  • Round table 


Supported by an unrestricted educational grant from Cardiac Dimensions


4:00 PM - 5:00 PM (BST)
Plenary Session
Part 5: Session 9 - New technologies for HF management

Chairs – William Abraham and John Cleland

  • Telemonitoring for heart failure – Lynne Stevenson
  • MONITOR HF: what do we learn about haemodynamic monitoring? – Jasper Brugts
  • Highlights of innovation and technologies in HF – Daniel Burkhoff


7:00 PM - 8:00 PM (BST)
Plenary Session
Part 6: Session 10 - Special Populations

Chairs – Maria Cecilia Bahit and Horst Sievert

  • Targeting FMR in HF – Klaus Witte
  • Managing TR HF – Paul Sorajja
  • Secondary pulmonary hypertension in HF – Stephan Rosenkranz
  • Mitja Lainscak 


8:00 PM - 9:00 PM (BST)
Meet the Expert
Management of patients with HFpEF: What did we learn from our HFrEF patients

  • Welcome and introduction - Giuseppe Rosano
  • Barriers for implementation - Clara Ines Saldarriaga 
  • Learnings from HFrEF for HFpEF - Gianluigi Savarese 
  • Panel discussion 


Supported by an unrestricted educational grant from AstraZeneca



Register for free

Faculty

William Abraham
Prof William Abraham
Ohio State University College of Medicine, Ohio, US
Marianna Adamo
Dr Marianna Adamo
University of Brescia, Brescia, IT
Stefan Anker
Prof Stefan Anker
Charité Campus Virchow-Klinikum, Berlin, DE
Maria Cecilia Bahit
Dr Maria Cecilia Bahit
INECO Neurociencias Oroño, Santa Fe, AR
Ahmed Bennis
Prof Ahmed Bennis
Ibn Rochd University Hospital, Casablanca, MA
Deepak Bhatt
Dr Deepak Bhatt
Mount Sinai Heart, New York, US
Frieder Braunschweig
Prof Frieder Braunschweig
Karolinska University Hospital, Stockholm, SE
Jasper Brugts
Dr Jasper Brugts
Erasmus University Medical Centre, Rotterdam, NL
Daniel Burkhoff
Dr Daniel Burkhoff
Cardiovascular Research Foundation, New York, US
Javed Butler
Dr Javed Butler
Baylor Scott and White Research Institute, Texas, US
Michael Bӧhm
Prof Michael Bӧhm
Saarland University Hospital, Homburg, DE
Patricia Campbell
Dr Patricia Campbell
Craigavon Area hospital, Portadown, UK
Alicia Chan
Dr Alicia Chan
Western HeartCare, Henley Beach, AU
Ovidiu Chioncel
Prof Ovidiu Chioncel
Institute for Cardiovascular Diseases C.C. Iliescu, Bucharest, RO
John Cleland
Prof John Cleland
University of Glasgow, Glasgow, UK
Javier de Juan Bagudá
Dr Javier de Juan Bagudá
University Hospital 12 de Octubre, Madrid, ES
Wolfram Doehner
Prof Wolfram Doehner
Charité – Universitätsmedizin Berlin, Berlin, DE
Giulia Ferrannini
Dr Giulia Ferrannini
Karolinska Institute, Stockholm, SE
Joao Ferreira
Dr Joao Ferreira
University of Porto, Porto, PT
Gerasimos Filippatos
Prof Gerasimos Filippatos
National and Kapodistrian University of Athens, Athens, GR
Marianna Fontana
Prof Marianna Fontana
University College London, London, UK
Marat Fudim
Dr Marat Fudim
Duke University, Durham, US
Ewa Jankowska
Prof Ewa Jankowska
Wrocław Medical University, Wrocław, PL
Paul Kalra
Prof Paul Kalra
Portsmouth Hospitals NHS Trust, Portsmouth, UK
Fabian Knebel
Prof Fabian Knebel
Sana Klinikum Berlin Lichtenberg, Berlin, DE
Mikhail Kosiborod
Dr Mikhail Kosiborod
Saint Luke’s Mid America Heart Institute, Kansas City, US
Arnt Kristen
Prof Arnt Kristen
University of Heidelberg, Heidelberg, DE
Ahmad Masri
Dr Ahmad Masri
Oregon Health & Science University, Portland, US
John McMurray
Prof John McMurray
University of Glasgow, Glasgow, UK
Robert John Mentz
Dr Robert John Mentz
Duke University, Durham, US
Marco Metra
Prof Marco Metra
University of Brescia, Brescia, IT
Brenda Moura
Dr Brenda Moura
Military Hospital, Porto, PT
Milton Packer
Dr Milton Packer
Baylor University Medical Center, Texas, US
Mark Petrie
Prof Mark Petrie
University of Glasgow, Glasgow, UK
Massimo Piepoli
Prof Massimo Piepoli
University of Milan, Milan, IT
Ileana Pina
Dr Ileana Pina
Thomas Jefferson University, Philadelphia, US
Piotr Ponikowski
Prof Piotr Ponikowski
Wrocław Medical University, Wrocław, PL
Giuseppe Rosano
Prof Giuseppe Rosano
St Georges Medical School, London, UK
Stephan Rosenkranz
Prof Stephan Rosenkranz
Heart Center at the University of Cologne, Cologne, DE
Clara Ines Saldarriaga
Prof Clara Ines Saldarriaga
CardioVID clinic, Medellin, CO
Gianluigi Savarese
Dr Gianluigi Savarese
Karolinska Institute, Stockholm, SE
Horst Sievert
Prof Horst Sievert
CardioVascular Center Frankfurt, Frankfurt, DE
Andrew Sindone
Dr Andrew Sindone
Concord Hospital, Sydney, AU
Paul Sorajja
Dr Paul Sorajja
Minneapolis Heart Institute, Minneapolis, US
Brett Sperry
Dr Brett Sperry
Saint Luke's Mid America Heart Institute, Kansas City, US
Lynne Stevenson
Dr Lynne Stevenson
Vanderbilt University Medical Center, Nashville, US
John Teerlink
Dr John Teerlink
San Francisco Veterans Affairs Medical Center, San Francisco, US
Daniela Tomasoni
Dr Daniela Tomasoni
Civil Hospital of Brescia, Brescia, IT
Muthiah Vaduganathan
Dr Muthiah Vaduganathan
Brigham and Women’s Hospital, Massachusetts, US
Peter Van De Meer
Dr Peter Van De Meer
University Medical Centre Groningen, Groningen, NL
Harriette van Spall
Dr Harriette van Spall
McMaster University, Hamilton, CA
Stephan von Haehling
Prof Stephan von Haehling
University Medicine Göttingen, Göttingen, DE
Klaus Witte
Prof Klaus Witte
RWTH University Hospital Aachen, Aachen, DE
Aaron Wong
Dr Aaron Wong
Princess of Wales Hospital, Wales, UK
Yuhui Zhang
Prof Yuhui Zhang
Cardiovascular Institute & Fuwai Hospital, Beijing, CN
Shelley Zieroth
Prof Shelley Zieroth
St. Boniface Hospital, Winnipeg, CA

Learning Objectives

  • Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
  • Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
  • Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
  • Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
  • Translate the findings of recent studies and guidelines into optimal patient management

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Sponsors

Gold:

Bronze:

If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com

About Translational Medicine Academy

Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.

Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.

For more information on TMA, please visit www.tmacademy.org.

About Radcliffe Cardiology

We are Radcliffe, a knowledge network for the cardiovascular community

We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.

We bring medical knowledge to life

From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.

Our work is underpinned by 3 core principles:

  • We build on the best science
  • We work hands-on with our community
  • We bring fresh thinking


Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.

For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com